Dr. Sandra Demaria

I

s a Professor at Weill Cornell Medicine and Board-certified anatomic pathologist with twenty-year experience in pathologic diagnosis of breast and other cancers. She is a member of the International Immuno-Oncology Biomarker Working Group and has contributed to the development of guidelines for standardized assessment of the lymphocytic infiltrate in breast cancer. For this study she will assess the ImmunoScore in the pre-treatment biopsy and post-treatment resection specimen of all patients enrolled in the MCT trial.